During the past recent years, various therapies emerged in the era of breast cancer. Breast
cancer is a heterogeneous disease in which genetic and environmental factors are involved …

Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high
heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the …

Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for
multiple cancer types. However, the emergence of resistance as well as inadequate …

Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops
resistance to chemotherapy. An unresolved question is whether resistance is caused by the …